Benchmark Maintains Speculative Buy on OncoCyte, Lowers Price Target to $5
Portfolio Pulse from richadhand@benzinga.com
Benchmark analyst Bruce Jackson maintains a Speculative Buy on OncoCyte (NASDAQ:OCX) but lowers the price target from $9 to $5.

August 24, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
OncoCyte's price target has been lowered from $9 to $5 by Benchmark, though the Speculative Buy rating is maintained.
The lowering of the price target by Benchmark indicates a potential decrease in the stock's value. However, the maintenance of the Speculative Buy rating suggests that the stock still has potential upside, albeit at a lower price point. This could lead to short-term negative pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100